Natural history studies document disease progression by observing diseases in their unmodified state, deepening our understanding of how conditions evolve over time. In the drug development process, they serve as external comparators by providing baseline data against which treatment effects can be assessed. They act as fundamental benchmarks that inform trial design and evidence generation when randomized controls are impractical.
In this webinar, Sano’s Senior Project Manager Clare Clarke shares the approach Sano employs to achieve its mission of accelerating the world’s transition to precision medicine. She outlines the seamless integration of recruitment, biomarker testing, and engagement within research trials, and provides an overview of Sano’s technology. This is the first in a series of webinars that will showcase various aspects of Sano’s product.
Many hereditary diseases are clinically manageable when detected early, yet most carriers are identified only after symptoms appear. Population genomic screening addresses this gap by testing large populations of otherwise healthy individuals to find genomic variants associated with clinically actionable conditions. These conditions can often be prevented or mitigated when detected early. By identifying individuals at risk of preventable and treatable conditions, screening directly reduces morbidity and mortality when results are acted upon.
In this webinar, “Parkinson's disease: Engagement, screening, and retention," Sano CEO and Co-Founder Patrick Short shares a case study of Sano’s work on a genetic Parkinson’s disease clinical trial. He explores the methodologies used for this cutting-edge program, and describes the success of the project.
Precision medicine represents a fundamental shift in how treatments are developed and delivered. Rather than relying on population-level assumptions about how patients will respond, it accounts for individual variability in genes, environment, and lifestyle to guide clinical decisions with greater accuracy. Our latest whitepaper examines how the adoption of genetic information is changing clinical practice, both for improving patient outcomes and for the efficiency of healthcare delivery.
Over the last two decades, following the landmark achievement of sequencing the first complete human genome, a suite of powerful genetic tools has emerged. Gene panel testing, whole exome sequencing, and whole genome sequencing are now pivotal in gathering detailed genetic information. In the United States, newborn screening is state-mandated, yet the conditions screened and the technologies used vary considerably between jurisdictions. The integration of advanced genomic tools into neonatal care holds the potential for meaningful genetic insight from the moment of birth, but only if access keeps pace with capability.
Tissue engineering and regenerative medicine (TERM), integral to the evolution of precision medicine, are advancing methods to regenerate or repair damaged tissues and organs. Tissue engineering uses cells, scaffolds, and growth factors to regenerate or replace damaged or diseased tissues, while regenerative medicine combines tissue engineering with other treatments like gene therapy, immunomodulation and cell-based therapy to induce tissue regeneration within the body.
Last year, Sano CEO Dr. Patrick Short presented a webinar called “Genetics Essentials for Clinical Research professionals.” In it, he explained the fundamentals of genetics in clinical research, explored the trends propelling genetics in drug development, and shared practical applications in drug discovery, development, and delivery. Now, we’re back with part 2, which goes beyond fundamentals and is presented by Sano COO Charlotte Guzzo.
Genomic screening is changing how clinicians and families approach prenatal and neonatal care. These tests, which analyze fetal or newborn DNA for chromosomal conditions and genetic disorders, provide early information that can shape medical decisions, care planning, and long-term health management. But the rapid expansion of these capabilities also introduces new questions around access, consent, and clinical integration. Our latest report, "Precision from the start: Balancing progress and principles in prenatal and neonatal care," examines these advancements and the ethical dilemmas they present.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Wendy Chung, Dr. Holly Peay, and Kira Dineen, offered a deep dive into the latest advancements in newborn screening, showcasing how cutting-edge genetic technologies are paving the way for a new era in medical care for our youngest patients. The link to the full webinar is here; a brief summary is below for easy reference.